TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15185885

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 50
Study: 11930971

Group type: EXPERIMENTAL
Intervention: Fast Track preventive intervention
Number of subjects: 0
Study: 9514453

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg/day
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2100
Study: 7698708

Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms/day subcutaneously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (3 x 0.9% saline solution subcutaneously)
Number of subjects: 10
Study: 2720457

Group type: EXPERIMENTAL
Intervention: E-Z Derm dressing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 32
Study: 335793

Group type: COMPARATOR
Intervention: p.o. acenocoumarin (control)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: s.c. heparin alone
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: s.c. heparin + p.o. acenocoumarin
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: s.c. heparin (5000 IU twice daily)
Number of subjects: 313
Study: 31480245

Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 42

Group type: COMPARATOR
Intervention: Savoury crackers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Water (zero energy control)
Number of subjects: 42
Study: 29031393

Group type: EXPERIMENTAL
Intervention: FO group (400mL/day of fish oil-enriched dairy drink with 320mg DHA + 72mg EPA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CT group (400mL/day of non-supplemented dairy drink)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FO group
Number of subjects: 46
Study: 25833163

Group type: EXPERIMENTAL
Intervention: Hib-MenAC vaccine (administered in 2-dose series for 6-23 months and single dose for 2-5 years)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Hib-MenAC vaccine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Licensed vaccines (control group)
Number of subjects: 1200
Study: 23536104

Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 35
Study: 22056152

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT) (65‐69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) only
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Number of subjects: 1205
Study: 19336625

Group type: EXPERIMENTAL
Intervention: Lispro mix 75/25 (LM75/25)
Number of subjects: 2041
Study: 16491367

Group type: EXPERIMENTAL
Intervention: oestradiol/dydrogesterone
Number of subjects: 193

Group type: COMPARATOR
Intervention: CEE/norgestrel
Number of subjects: 193
Study: 15488342

Group type: EXPERIMENTAL
Intervention: METH+/MJ- (n=26)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: METH+/MJ+ (n=27)
Number of subjects: 94
Study: 11009745

Group type: EXPERIMENTAL
Intervention: Peer-comparison feedback (physician 'report cards')
Number of subjects: 48

Group type: COMPARATOR
Intervention: General information about monitoring functional status (Control)
Number of subjects: 48
Study: 8979644

Group type: EXPERIMENTAL
Intervention: PM exercise (16:00 hrs)
Number of subjects: 24
Study: 2004261

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation in healthy subjects
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation in patients with MS
Number of subjects: 22
Study: 7130340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low dose estrogen (1/0.5 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Medium dose estrogen (2/1 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High dose estrogen (4/2 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All hormone groups (low, medium, high)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Untreated postmenopausal women
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Post-treatment values of S-aPh and U-HyPro
Number of subjects: 92
Study: 30798000

Group type: EXPERIMENTAL
Intervention: 1000 IU per day vitamin D supplementation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 28214948

Group type: EXPERIMENTAL
Intervention: Fiix-warfarin patients
Number of subjects: 1143

Group type: COMPARATOR
Intervention: PT-warfarin patients
Number of subjects: 1143
Study: 26526494

Group type: EXPERIMENTAL
Intervention: High fidelity simulation (SimNewB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low fidelity simulation (Resusci(®) Baby Basic)
Number of subjects: 101
Study: 24676313

Group type: EXPERIMENTAL
Intervention: 15 mg/day of Zn for 6 months
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 30 mg/day of Zn for 6 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 108
Study: 22554019

Group type: EXPERIMENTAL
Intervention: 4% liquid lidocaine on cotton swabs
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3.5% lidocaine gel
Number of subjects: 50
Study: 20441720

Group type: EXPERIMENTAL
Intervention: Venlafaxine in extensive metabolizers (EMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine in poor metabolizers (PMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 17920374

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (beta(1) blockade)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 14
Study: 16135174

Group type: EXPERIMENTAL
Intervention: Fixed dose regimen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adjustable dose regimen
Number of subjects: 69
Study: 11755936

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg per oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10075094

Group type: EXPERIMENTAL
Intervention: Thyroxine (8 microg/kg birthweight/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7484325

Group type: EXPERIMENTAL
Intervention: Two scales based on the Fagerstrom Tolerance Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two subsets of three items from each scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reports of using smokeless tobacco within 30 min of waking
Number of subjects: 0
Study: 2913252

Group type: EXPERIMENTAL
Intervention: Topical tetracycline used as a suspension in a gelatin sponge placed in the sockets of extracted mandibular third molars.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 0
Study: 1093426

Group type: EXPERIMENTAL
Intervention: Oral diazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular diazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oral and intramuscular diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study: 30137250

Group type: EXPERIMENTAL
Intervention: HIV‐1 participants with TB coinfection
Number of subjects: 860
Study: 28860395

Group type: EXPERIMENTAL
Intervention: Closing wedge high tibial osteotomy (HTO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Opening wedge high tibial osteotomy (HTO)
Number of subjects: 70
Study: 26032346

Group type: EXPERIMENTAL
Intervention: Crossed brassiere straps
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parallel brassiere straps
Number of subjects: 15
Study: 23560884

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (2 μg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous fentanyl (2 μg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 30
Study: 21194181

Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 76
Study: 19929258

Group type: EXPERIMENTAL
Intervention: Autologous cultured BM-derived MSCs along with standard wound dressing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard wound dressing regimen
Number of subjects: 24
Study: 21610662

Group type: EXPERIMENTAL
Intervention: FRAX-based probabilities calculated without BMD
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: FRAX-based probabilities calculated with BMD
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Women with a prior fragility fracture
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Criterion A (BMD T-score of -2.5)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Criterion D (prior fracture plus fixed threshold)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Criteria B and C (age-dependent threshold)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Criteria B and C
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Criteria A and D
Number of subjects: 1608
Study: 16020071

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 12512928

Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 3 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 microg oral misoprostol every 6 hours
Number of subjects: 0
Study: 10335039

Group type: EXPERIMENTAL
Intervention: rhGH (recombinant human growth hormone) administered daily subcutaneously for 12 months, initial dose 0.125 IU/kg b.w./week, adjusted to maintain serum IGF-1 levels of 280-350 micrograms/L.
Number of subjects: 18
Study: 7856175

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 715
Study: 2688475

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia
Number of subjects: 381

Group type: COMPARATOR
Intervention: Intermittent epidural analgesia
Number of subjects: 381
Study: 4569549

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) infused simultaneously with oxytocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxytocin (Syntocinon) administered in escalating doses
Number of subjects: 20
Study: 11392598

Group type: EXPERIMENTAL
Intervention: Misoprostol (100 microg intravaginally every 4 h)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Oxytocin (by intravenous infusion)
Number of subjects: 360
Study: 31183444

Group type: EXPERIMENTAL
Intervention: D3 lymph node dissection
Number of subjects: 768

Group type: COMPARATOR
Intervention: D2 lymph node dissection
Number of subjects: 768
Study: 29316130

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 761

Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 761
Study: 27434834

Group type: EXPERIMENTAL
Intervention: HIV-affected group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Children from families with a surviving grandparent with HIV
Number of subjects: 79

Group type: COMPARATOR
Intervention: Family-based, cognitive-behavioral HIV intervention
Number of subjects: 79
Study: 25185483

Group type: EXPERIMENTAL
Intervention: Federal audits
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: State audits
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control condition (no audits)
Number of subjects: 85
Study: 22580944

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 12
Study: 20399212

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo progesterone
Number of subjects: 18
Study: 17654043

Group type: EXPERIMENTAL
Intervention: 3 g of l-arginine and 75 mg of acetylsalicylic acid daily for 20 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 0
Study: 15890494

Group type: EXPERIMENTAL
Intervention: High intensity stimuli
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Invalid cues
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cue validity effects
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Evoked electric potential
Number of subjects: 6
Study: 11796357

Group type: EXPERIMENTAL
Intervention: Caspofungin (35, 50, or 70 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Amphotericin B (0.5 mg/kg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Caspofungin (any dose)
Number of subjects: 140
Study: 9787370

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 463

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 463
Study: 7658946

Group type: EXPERIMENTAL
Intervention: 80% of the lactic acidosis threshold (LAT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 25% delta
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 50% delta
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 75% delta
Number of subjects: 27
Study: 2698943

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide + amiloride
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 184912

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) added to 15 months' maintenance actinomycin D (AMD) in Gp I patients under 2 years of age
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Combined actinomycin D (AMD) and vincristine (VCR)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Preoperative vincristine (VCR) in Gp IV patients
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group (no postoperative RT) in Gp I patients under 2 years of age
Number of subjects: 606
Study: 30843046

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 30939487

Group type: EXPERIMENTAL
Intervention: COLM‐SST (25 mg of caraway oil and 20.75 mg of L‐menthol per capsule, at 2 capsules per dose, twice per day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 28577848

Group type: EXPERIMENTAL
Intervention: Cryothermal energy only (group 1)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Combination of cryothermal and bipolar radiofrequency (group 2)
Number of subjects: 709
Study: 25521219

Group type: EXPERIMENTAL
Intervention: Prophylactic FFP
Number of subjects: 81

Group type: COMPARATOR
Intervention: Reactive FFP
Number of subjects: 81
Study: 23891420

Group type: COMPARATOR
Intervention: CDC Control
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Facts Only
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Facts and Myths
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Facts, Myths, and Refutations
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 125
Study: 20805005

Group type: EXPERIMENTAL
Intervention: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d) supplementation
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 19878827

Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 250 mm Hg (subgroup 1)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 450 mm Hg (subgroup 2)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Phacoemulsification under vacuum of 600 mm Hg (subgroup 3)
Number of subjects: 998
Study: 16525137

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for 52 weeks
Number of subjects: 715

Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily for 52 weeks
Number of subjects: 715
Study: 12694427

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing chlorhexidine (0.05%), cetylpyridinium chloride (0.05%), and zinc-lactate (0.14%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthrinse without active ingredients
Number of subjects: 40
Study: 10809816

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) in combination with cyclosporin and prednisone (MMF+)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cylosporin and prednisone (MMF-)
Number of subjects: 84
Study: 8852484

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3 g/day with triglyceride preparation; 7.7 g/day with ethyl-ester preparation)
Number of subjects: 8
Study: 1537778

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6391667

Group type: EXPERIMENTAL
Intervention: Antacid given seven times a day combined with 600 mg BID of cimetidine (C + A7)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Antacid given four times a day combined with cimetidine BID (C + A4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Antacid alone seven times daily (A7)
Number of subjects: 8

Group type: COMPARATOR
Intervention: All active treatments (C + A7, C + A4, A7) compared to placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine morning dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine coadministration with antacid
Number of subjects: 8
Study: 31633760

Group type: EXPERIMENTAL
Intervention: Pediatric-specific tumescent vasopressor solution and vasopressor-soaked topical compresses
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard hemostasis management)
Number of subjects: 61
Study: 29916084

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 17

Group type: COMPARATOR
Intervention: CGRP
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sildenafil and CGRP
Number of subjects: 17
Study: 26923086

Group type: EXPERIMENTAL
Intervention: Protected mealtimes implementation
Number of subjects: 0
Study: 24768940

Group type: EXPERIMENTAL
Intervention: Integrated telemedicine counseling (ITM) delivered via 2-way webcams in physician's office
Number of subjects: 566

Group type: COMPARATOR
Intervention: Quitline counseling delivered by telephone (Phone)
Number of subjects: 566
Study: 22184058

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 1366

Group type: COMPARATOR
Intervention: No maternal smoking during pregnancy
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Urinary cotinine >1.3 ng ml(‐1)
Number of subjects: 1366
Study: 20698896

Group type: EXPERIMENTAL
Intervention: HCAHPS graphs
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Relative's narrative e-mail
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Inconsistent information between HCAHPS data and e-mail narrative
Number of subjects: 309
Study: 17548089

Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 or 2.5 mg/d)
Number of subjects: 3240

Group type: COMPARATOR
Intervention: CEE-MPA (continuous combined conjugated equine estrogen and medroxyprogesterone acetate)
Number of subjects: 3240
Study: 16342344

Group type: EXPERIMENTAL
Intervention: Color Doppler myocardial imaging in patients with uncontrolled hypertension
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Color Doppler myocardial imaging in patients with controlled hypertension
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters in patients with uncontrolled hypertension
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters in patients with controlled hypertension
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 33
Study: 15259390

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clock-related cognition tests
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clock face copying and time representation selection
Number of subjects: 30
Study: 10505303

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) antibody
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: No obvious aetiology
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Hepatitis B core antibody (HBcAb)
Number of subjects: 2166
Study: 8949812

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TOE) with automated endocardium detection
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Changes in MD (AL) derived stroke volume
Number of subjects: 15
Study: 2022522

Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioactive chromic phosphate
Number of subjects: 69
Study: 7039282

Group type: EXPERIMENTAL
Intervention: Lorcainide, 100 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 10
Study: 29660951

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation with effortful swallowing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham neuromuscular electrical stimulation with effortful swallowing
Number of subjects: 18
Study: 27043946

Group type: EXPERIMENTAL
Intervention: Continuous application of local anaesthetic through subfascial catheter
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuous application of local anaesthetic through subcutaneous catheter
Number of subjects: 52
Study: 25780881

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) 100 mg/kg infusion 6 hours before donor operation and subsequent infusion of 100 mg/kg every 6 hours until organ removal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA)
Number of subjects: 40
Study: 23851059

Group type: EXPERIMENTAL
Intervention: Adaptive cardiac resynchronization therapy (aCRT) with synchronized left ventricular pacing (sLVP)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Echocardiography-optimized biventricular pacing (BVP)
Number of subjects: 478
Study: 20855072

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Niacin 1500 mg
Number of subjects: 201